Lapatinib in early breast cancer--questions to be resolved

Lancet Oncol. 2013 Jan;14(1):11-2. doi: 10.1016/S1470-2045(12)70571-5. Epub 2012 Dec 10.

Author

Per Eystein Lønning¹

Affiliation

¹ Section of Oncology, Institute of Medicine, University of Bergen, Bergen, Norway. per.lonning@helse-bergen.no

PMID: 23234762
DOI: 10.1016/S1470-2045(12)70571-5

No abstract available

Publication types

Comment

MeSH terms

Breast Neoplasms / drug therapy*
Disease-Free Survival*
Female
Humans
Lapatinib
Quinazolines / administration & dosage*
Receptor, ErbB-2 / metabolism*

Substances

Quinazolines
Lapatinib
ERBB2 protein, human
Receptor, ErbB-2